254 results on '"Martin, Emily T"'
Search Results
2. Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity — IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
3. Post-recovery health domain scores among outpatients by SARS-CoV-2 testing status during the pre-Delta period
4. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis
5. Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022
6. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
7. Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study
8. Acute respiratory infections among individuals seeking outpatient care in the states of Washington and Michigan by pregnancy status, 2011–2016
9. Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018–2022
10. 1789. Comparison of influenza vaccine effectiveness estimates from the US Influenza Vaccine Effectiveness Network and Electronic Health Record Source Population Data, 2021-2022
11. 900. The Epidemiology of Viral Coinfections within Households with Children
12. 302. Investigating NAI Titer as a Neutralizing IAV Correlate of Protection
13. 1161. Effectiveness of the Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Infections in Outpatient Immunocompromised Adults, 2017-2018
14. 890. Environmental Air and Surface Sampling of Respiratory Viruses in Child Care Centers
15. 1745. Respiratory Syncytial Virus Surveillance of Child Care Attendees, Family Members, and Child Care Providers
16. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
17. 2082. Effectiveness of Bivalent mRNA Vaccines in Preventing SARS-CoV-2 Infection Among Children Aged 5-17 years: an Evaluation of Multicenter Prospective Cohorts, United States, September 2022 - January 2023
18. 1108. Severity of Illness among Adults Hospitalized with Respiratory Syncytial Virus Compared with COVID-19 and Influenza — IVY Network, 25 Hospitals, 20 U.S. States, January 31, 2022 – April 11, 2023
19. 2712. Respiratory syncytial virus (RSV) pre-fusion F antibody titers in hematopoietic cell transplant recipients with upper versus lower respiratory tract infections
20. 2638. Patterning of high-risk comorbidity associated with vaccination but not influenza status among hospitalized patients in an influenza test-negative design cohort
21. 1097. A Prospective Evaluation of SARS-CoV-2 Shedding and Evolution in Immunocompromised Hosts During the Omicron Period — IVY Network, 5 U.S. States, April 11, 2022 – February 1, 2023
22. Antibody response to symptomatic infection with SARS-CoV-2 Omicron variant viruses, December 2021—June 2022
23. Incidence and Transmission of SARS-CoV-2 in US Child Care Centers After COVID-19 Vaccines
24. Anti-SARS-CoV-2 Antibody Levels Associated with COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu VE Network, October 2021–June 2022
25. SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis
26. Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study
27. Immune response to COVID-19 vaccination in a population with a history of elevated exposure to per- and polyfluoroalkyl substances (PFAS) through drinking water
28. Risk factors for infection with influenza A(H3N2) virus on a US university campus, October–November 2021
29. Comparison of mRNA Vaccine Effectiveness against COVID-19-associated Hospitalization by Vaccination Source: Immunization Information Systems, Electronic Medical Records, and Self-Report — IVY Network, February 1*August 31, 2022
30. A rapid and flexible microneutralization assay for serological assessment of influenza viruses
31. Evaluating reduced effectiveness after repeat influenza vaccination while accounting for confounding by recent infection and within-season waning
32. Half of adults hospitalized with COVID-19 are still impacted one year later
33. K‐medoids clustering of hospital admission characteristics to classify severity of influenza virus infection
34. Respiratory virus circulation during the first year of the COVID‐19 pandemic in the Household Influenza Vaccine Evaluation (HIVE) cohort
35. Comparing the Etiology of Viral Acute Respiratory Illnesses Between Children Who Do and Do Not Attend Childcare
36. Relationship between Telework Experience and Presenteeism during COVID-19 Pandemic, United States, March–November 2020
37. Prevalence and Clinical Outcomes of Respiratory Syncytial Virus versus Influenza in Adults Hospitalized with Acute Respiratory Illness from a Prospective Multicenter Study
38. Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants
39. Comparison of mRNA Vaccine Effectiveness Against COVID-19-Associated Hospitalization by Vaccination Source: Immunization Information Systems, Electronic Medical Records, And Self-Report — Ivy Network, February 1–August 31, 2022
40. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season
41. Respiratory Virus Circulation during the First Year of the COVID-19 Pandemic in the Household Influenza Vaccine Evaluation (HIVE) Cohort
42. Burden of medically attended influenza infection and cases averted by vaccination – United States, 2016/17 through 2018/19 influenza seasons
43. SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza
44. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries
45. Epidemiology of RSV-A and RSV-B in Adults and Children with Medically-Attended Acute Respiratory Illness over Three Seasons
46. Comparisons of Respiratory Syncytial Virus (RSV) and Influenza: Population Characteristics and Clinical Outcomes in Hospitalized Adults
47. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States
48. Rapid transmission and tight bottlenecks constrain the evolution of highly transmissible SARS-CoV-2 variants
49. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
50. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.